CN108025054B - 用于治疗和/或预防肿瘤的沙粒病毒和用于制备具有(改善的)肿瘤消退性能的沙粒病毒的方法 - Google Patents

用于治疗和/或预防肿瘤的沙粒病毒和用于制备具有(改善的)肿瘤消退性能的沙粒病毒的方法 Download PDF

Info

Publication number
CN108025054B
CN108025054B CN201680030624.5A CN201680030624A CN108025054B CN 108025054 B CN108025054 B CN 108025054B CN 201680030624 A CN201680030624 A CN 201680030624A CN 108025054 B CN108025054 B CN 108025054B
Authority
CN
China
Prior art keywords
tumor
cancer
cells
arenavirus
arenaviruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680030624.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN108025054A (zh
Inventor
卡尔·塞班斯坦·兰
H.卡尔卡万
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vinolusence Biotechnology Co ltd
Original Assignee
Abalos Treatment Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abalos Treatment Ltd filed Critical Abalos Treatment Ltd
Publication of CN108025054A publication Critical patent/CN108025054A/zh
Application granted granted Critical
Publication of CN108025054B publication Critical patent/CN108025054B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680030624.5A 2015-04-17 2016-04-15 用于治疗和/或预防肿瘤的沙粒病毒和用于制备具有(改善的)肿瘤消退性能的沙粒病毒的方法 Active CN108025054B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102015207036.0 2015-04-17
DE102015207036.0A DE102015207036A1 (de) 2015-04-17 2015-04-17 Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
PCT/EP2016/058347 WO2016166285A1 (de) 2015-04-17 2016-04-15 Arenaviren zur anwendung bei der behandlung und/oder vorbeugung von tumoren sowie verfahren zur herstellung von arenaviren mit (verbesserten) tumorregressiven eigenschaften

Publications (2)

Publication Number Publication Date
CN108025054A CN108025054A (zh) 2018-05-11
CN108025054B true CN108025054B (zh) 2022-12-23

Family

ID=55759589

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680030624.5A Active CN108025054B (zh) 2015-04-17 2016-04-15 用于治疗和/或预防肿瘤的沙粒病毒和用于制备具有(改善的)肿瘤消退性能的沙粒病毒的方法

Country Status (8)

Country Link
US (3) US20180117137A1 (cg-RX-API-DMAC7.html)
EP (1) EP3283104B1 (cg-RX-API-DMAC7.html)
JP (2) JP7039037B2 (cg-RX-API-DMAC7.html)
CN (1) CN108025054B (cg-RX-API-DMAC7.html)
CA (1) CA2982873A1 (cg-RX-API-DMAC7.html)
DE (1) DE102015207036A1 (cg-RX-API-DMAC7.html)
ES (1) ES3017684T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016166285A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811093T3 (es) 2014-11-13 2021-03-10 Univ Geneve Arenavirus trisegmentados como vectores de vacunas
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
WO2017076988A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
CN110719788A (zh) * 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒
DE102018215551A1 (de) * 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
WO2022180203A1 (en) 2021-02-26 2022-09-01 Abalos Therapeutics Gmbh New virus particles for therapeutic purposes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034461B4 (de) 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
US7994221B2 (en) * 2004-12-06 2011-08-09 Siga Technologies, Inc. Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
WO2011056993A1 (en) * 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften

Also Published As

Publication number Publication date
EP3283104A1 (de) 2018-02-21
BR112017022022A8 (pt) 2023-03-07
JP7039037B2 (ja) 2022-03-22
JP7273102B2 (ja) 2023-05-12
CN108025054A (zh) 2018-05-11
JP2021129589A (ja) 2021-09-09
CA2982873A1 (en) 2016-10-20
US11801294B2 (en) 2023-10-31
US20190151436A1 (en) 2019-05-23
WO2016166285A1 (de) 2016-10-20
ES3017684T3 (en) 2025-05-13
DE102015207036A1 (de) 2016-10-20
HK1251168A1 (zh) 2019-01-25
JP2018515130A (ja) 2018-06-14
EP3283104C0 (de) 2024-12-11
US12409217B2 (en) 2025-09-09
US20240252611A1 (en) 2024-08-01
BR112017022022A2 (pt) 2019-01-22
US20180117137A1 (en) 2018-05-03
EP3283104B1 (de) 2024-12-11

Similar Documents

Publication Publication Date Title
US12409217B2 (en) Administering a lymphocytic choriomeningtitis virus (LCMV) with improved tumor regression properties
JP6794442B2 (ja) 新規な遺伝子組換えワクシニアウイルス
CN102174479B (zh) 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用
CN108307642B (zh) 改造的白介素12及其在制备治疗肿瘤药物中的用途
CN115397838A (zh) 溶瘤病毒样囊泡的组合物和使用方法
US20250122244A1 (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
EP2826856B9 (en) Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
CN115804853A (zh) 包含rna分子的组合物及其在制备瘤内注射剂中的用途
CN115702940A (zh) 包含环状rna分子的制剂在制备治疗肿瘤的药物中的应用
BR112017022022B1 (pt) Uso de um vírus da coriomeningite linfocítica (lcmv) ou um vírus junin e composição compreende os mesmos
HK1251168B (en) Arenavirus for use in treatment of tumors in human
HK40122461A (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
WO2025234450A1 (ja) 改変がん細胞及びそれを含むがんワクチン組成物
CN118256561A (zh) 靶向双激酶aurka/cdk7的疫苗在治疗实体瘤中的应用
HK40054624A (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
CN120173884A (zh) 功能优化的嵌合抗原受体效应细胞及其在制备治疗急性髓系白血病的组合物中的应用
HK40054624B (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20191030

Address after: Essen, Germany

Applicant after: Vinolusence Biotechnology Co.,Ltd.

Address before: Essen, Germany

Applicant before: Karl Sebastan Lan

CB02 Change of applicant information
CB02 Change of applicant information

Address after: essen

Applicant after: Abalos treatment Ltd.

Address before: essen

Applicant before: Vinolusence Biotechnology Co.,Ltd.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Dusseldorf

Applicant after: Abalos treatment Ltd.

Address before: essen

Applicant before: Abalos treatment Ltd.

GR01 Patent grant
GR01 Patent grant